Divi's Laboratories Limited vs Symbiotec Pharmalab Limited
A side-by-side comparison of Divi's Laboratories Limited (DIVISLAB) and Symbiotec Pharmalab Limited (SYMBIOTEC) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Divi's Laboratories Limited leads DIVISLAB vs SYMBIOTEC on 10 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation22
- Profitability40
- Growth02
- Size & financial health40
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
DIVISLAB takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
SYMBIOTEC takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
DIVISLAB takes 4/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has been maintaining a healthy dividend payout of 31.0%", "Company is almost debt free."]
- − ["Stock is trading at 14.48 times its book value", "The company has delivered a poor sales growth of 8.7% over past five years."]
- + []
- − ["The company has delivered a poor sales growth of 6.5% over past five years.", "The company has delivered a poor profit growth of -2.2% over past five years.", "Though the company is reporting repeated profits, it is not paying out dividend"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.